Biotechnology R&D expenditure in selected countries 2020

Note: Biotechnology R&D expenditures in the business sector. Values are for 2020 or latest year available. For some countries, 2021 figures were already available.
For Austria and Germany, only dedicated biotech R&D firms are included.
For Canada, this includes medical biotechnology, environmental biotechnology, industrial biotechnology and agricultural biotechnology.
For the Russian Federation, a proxy indicator is used: R&D expenditure in Life Sciences (before 2011 - Living Systems), which include bioengineering, biocatalysis, biosynthesis and biosensor technologies, biomedical and veterinary technologies, genomics and pharmaco-genetics, living cell technologies.
For Germany and Lithuania, 2019 BERD was uses as 2020 BERD was not available.
For Latvia, this includes medical biotechnology, environmental biotechnology, industrial biotechnology and agricultural biotechnology.
For the United States, beginning in 2018, weights are adjusted to account for unit nonresponse and statistics are for companies that performed or funded $50,000 or more of R&D. Beginning in 2019, these company count estimates reflect a change in rounding methodology. For 2020, the Census Bureau has reviewed the data product for unauthorized disclosure of confidential information and has approved the disclosure avoidance practices applied.